Orlagh is a Postdoctoral Fellow and Nanomedicine team lead in the Porter Group at Monash Institute of Pharmaceutical Sciences (MIPS). Prior to award of her PhD, Orlagh worked as a research analyst in the pharmaceutical industry in Ireland for over five and a half years and as research assistant on industrial collaborations in Monash for four years. As a result, she maintains a strong translational focus to her work.

Orlagh’s research covers drug delivery more broadly, and specifically, enhancing oral uptake, lymphatic exposure and targeting of therapies for cancer and autoimmune diseases. This is achieved with multiple strategies, including active targeting, stromal modification and manipulation of physicochemical characteristics. Orlagh has extensive experience in preclinical study design and has established multiple disease models to examine new drug delivery strategies, including solid and disseminated cancers as well as collagen induced arthritis.